drugset / Trial / NCT01226901
A Phase I Study of MK-4827 for Treatment of Solid Tumors (MK-4827-005)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study will evaluate whether oral administration of MK-4827 to participants with advanced solid tumors is generally safe and well tolerated.
Timeline
- Start
- 2010-11
- Primary completion
- 2011-02
- Completion
- 2011-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Niraparib | Small molecule | 150 mg | Oral |
| Subject | Niraparib | Small molecule | 300 mg | Oral |